Testosterone Replacement Therapy

Testosterone replacement therapy (TRT) is a medically supervised intervention used to restore testosterone to physiologically adequate levels in individuals diagnosed with clinically confirmed deficiency. This page covers the definition and scope of TRT, the mechanisms through which it operates, the clinical scenarios in which it is applied, and the evidence-based boundaries that govern appropriate use. Understanding TRT requires situating it within the broader landscape of endocrinology and hormone management, where hormonal precision carries significant consequences for long-term health outcomes.

Definition and Scope

Testosterone replacement therapy refers to the exogenous administration of testosterone for the purpose of correcting a documented deficiency — a condition broadly termed hypogonadism. The U.S. Food and Drug Administration (FDA) has approved TRT specifically for the treatment of classical hypogonadism resulting from conditions affecting the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism), not for age-related testosterone decline in otherwise healthy males without a confirmed pathological diagnosis (FDA Drug Safety Communication on Testosterone Products).

The Endocrine Society defines biochemical hypogonadism as a morning serum total testosterone level below 300 ng/dL on at least 2 separate measurements, combined with consistent clinical symptoms (Endocrine Society Clinical Practice Guideline, 2018). Scope limitations are explicit: TRT is not indicated for infertility as a primary treatment, general well-being enhancement, or athletic performance improvement. The broader regulatory and clinical framework governing hormonal therapies in endocrinology is detailed in the regulatory context for endocrinology.

How It Works

Testosterone is the primary androgenic hormone produced in Leydig cells of the testes, regulated by the hypothalamic-pituitary-gonadal (HPG) axis. When endogenous production is insufficient, exogenous testosterone restores circulating androgen levels, binding to androgen receptors in target tissues including muscle, bone, liver, brain, and the cardiovascular system.

Approved delivery mechanisms fall into five primary categories:

1. Intramuscular injection — Testosterone cypionate or testosterone enanthate injected every 1–2 weeks; produces peak-and-trough fluctuations in serum levels.
2. Transdermal gel — Applied daily to skin; provides more stable serum concentrations but carries transfer risk to others via skin contact.
3. Transdermal patch — Applied nocturnally to mimic diurnal testosterone rhythm; adhesion issues affect consistency.
4. Subcutaneous pellet — Implanted every 3–6 months; offers prolonged, steady-state delivery without daily administration.
5. Buccal tablet — Applied to the gum mucosa twice daily; avoids first-pass hepatic metabolism.

Each formulation carries distinct pharmacokinetic profiles. Intramuscular injections produce supraphysiologic peaks immediately post-injection followed by sub-therapeutic troughs before the next dose — a fluctuation pattern associated with variable mood and energy symptoms. Subcutaneous pellets and gels produce more consistent area-under-the-curve exposure.

Exogenous testosterone suppresses endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion via negative feedback on the HPG axis. This suppression reduces intratesticular testosterone and sperm production, creating an important distinction from gonadotropin-based therapies (such as human chorionic gonadotropin, or hCG) that stimulate endogenous production and preserve fertility.

Common Scenarios

TRT is most frequently applied in the following clinical contexts:

• Primary hypogonadism — Conditions such as Klinefelter syndrome (47,XXY karyotype), bilateral orchiectomy, or chemotherapy-induced gonadal damage that result in direct testicular failure. These represent classical FDA-approved indications.
• Secondary hypogonadism — Pituitary tumors, hyperprolactinemia, or hypothalamic dysfunction that impair LH/FSH secretion. Full evaluation of the testosterone deficiency condition distinguishes primary from secondary pathology.
• Late-onset hypogonadism with pathological confirmation — Older males with both biochemically confirmed low testosterone and symptomatic burden, though the FDA's 2015 label update narrowed the approved indication specifically to classical hypogonadism.
• Transgender male (female-to-male) gender-affirming hormone therapy — The Endocrine Society's 2017 clinical practice guidelines for gender dysphoria recognize testosterone as the standard androgen therapy for masculinization, with target levels in the normal male physiologic range of 320–1,000 ng/dL (Endocrine Society Guidelines on Gender Dysphoria/Gender Incongruence, 2017).

Decision Boundaries

Clinical decision-making around TRT involves structured safety evaluation prior to initiation and during ongoing monitoring, guided by Endocrine Society and American Urological Association (AUA) frameworks.

Absolute contraindications include:

• Prostate cancer (confirmed or suspected)
• Male breast cancer
• Desire for near-term fertility (due to spermatogenesis suppression)
• Hematocrit exceeding 54% at baseline (AUA Guideline on Testosterone Deficiency, 2018)
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure

Cardiovascular risk represents an area of ongoing regulatory and clinical scrutiny. The FDA's 2015 label revision required all testosterone products to carry a warning about a possible increased risk of heart attack and stroke based on published observational data, though the causal relationship remains under investigation. The 2023 TRAVERSE trial — a randomized controlled trial of 5,246 participants — found no statistically significant increase in major adverse cardiovascular events with TRT compared to placebo in men with hypogonadism and preexisting cardiovascular disease or elevated risk (TRAVERSE Trial, NEJM 2023).

Monitoring during TRT follows a structured schedule: testosterone levels, hematocrit, and prostate-specific antigen (PSA) are assessed at 3–6 months after initiation and annually thereafter. Hematocrit elevation — polycythemia — is a dose-dependent effect of testosterone that increases thrombotic risk, requiring dose reduction or phlebotomy when hematocrit exceeds 54%.

Clinicians distinguish TRT from anabolic-androgenic steroid (AAS) misuse by dose range and intent: TRT targets restoration of physiologic serum testosterone (300–1,000 ng/dL), whereas AAS misuse typically involves supraphysiologic doses — often 10 to 100 times therapeutic levels — without medical diagnosis or supervision. This distinction carries legal significance, as testosterone is a Schedule III controlled substance under the Controlled Substances Act (DEA, 21 USC §812).

References

• FDA Drug Safety Communication: Testosterone Products and Cardiovascular Risk (2015)
• Endocrine Society Clinical Practice Guideline: Testosterone Therapy in Men with Hypogonadism (2018)
• Endocrine Society Clinical Practice Guideline: Gender Dysphoria/Gender Incongruence (2017)
• American Urological Association: Testosterone Deficiency Guideline (2018)
• TRAVERSE Trial, New England Journal of Medicine (2023)
• Drug Enforcement Administration: Controlled Substances Act, Schedule III

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)